Prime Highlights
- Eli Lilly plans to acquire three vaccine developers in deals worth up to $3.8 billion.
- The acquisitions signal the company’s renewed push into infectious disease prevention.
Key Facts
- Eli Lilly is a US-based pharmaceutical company known for medicines in obesity, diabetes and other treatment areas.
- Lilly will spend up to $1.5 billion on Curevo, $780 million on LimmaTech Biologics and $1.55 billion on Vaccine Company.
Background
Eli Lilly has announced plans to acquire three vaccine developers in deals worth up to $3.8 billion as the company increases its focus on infectious disease prevention. The acquisitions strengthen the drugmaker’s efforts to expand beyond its current product pipeline and enter the vaccine segment more aggressively.
The company said it will acquire Curevo, LimmaTech Biologics and Vaccine Company through separate agreements.
The move comes as Lilly continues its strong acquisition strategy, supported by growing revenue from its highly successful obesity drugs. Industry data also shows that the company’s deal spending in 2026 has already crossed levels seen in previous years.
The acquisitions signal Lilly’s renewed interest in infectious disease research after the company spent recent years focusing on other treatment areas. Company executives said the strategy aims to prevent diseases early rather than treat health problems after they develop.
Lilly will pay up to $1.5 billion for Curevo, which is developing amezosvatein, a vaccine for shingles. The company also agreed to acquire LimmaTech Biologics for up to $780 million. LimmaTech’s lead programme focuses on a vaccine against S. aureus, a major cause of infections after surgeries.
In addition, Lilly plans to acquire the Vaccine Company for up to $1.55 billion. The company is developing a vaccine targeting the Epstein-Barr virus, a highly contagious infection linked to several health conditions.
Analysts said the acquisitions fit Lilly’s existing research interests and represent relatively smaller investments compared to its broader growth strategy.
